To examine the functional dependence of CREBBP/EP300 in tumorigenesis in vivo, we took advantage of the C2C12 allograft tumor models and demonstrated that both VGLL2-NCOA2 and TEAD1-NCOA2-expressing C2C12 cells were able to generate aggressive tumors when allografted into nude mice, leading to termination of tumor-bearing mice at around 30 days post-injection. This evidence concerns the gene CREBBP and neoplasm.